Company: SISI
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010889
Chunk: 198

Company: SHINECO, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 2
Chunk 198
---
ization of debt issuance and other costs 
     (146,976) 
     (246,015) 
     99,039  
     (40.26)%
  
    Interest expenses, net 
     (262,239) 
     (250,899) 
     (11,340) 
     (4.52)%
  
    Loss before income tax benefit from continuing operations 
     (4,144,313) 
     (1,575,507) 
     (2,568,806) 
     163.05%
  
    Benefit for income taxes 
     (62,170) 
     (51,892) 
     (10,278) 
     19.81%
  
    Net loss from continuing operations 
     (4,082,143) 
     (1,523,615) 
     (2,558,528) 
     167.92%
  
    Net loss from discontinued operations 
     (12,529,001) 
     (2,845,113) 
     (9,683,888) 
     340.37%
  
    Net loss 
    $(16,611,144) 
    $(4,368,728) 
    $(12,242,416) 
     280.23%
  
    Comprehensive loss attributable to Shineco Inc. 
    $(15,076,328) 
    $(3,367,327) 
    $(11,709,001) 
     347.72%

Revenue

Currently, we, through our PRC subsidiaries, have
two major business segments from continuing operations. First, developing, producing and distributing innovative rapid diagnostic and
other products and related medical devices for the most common diseases; this segment is conducted through Biowin. Second, developing
and selling healthy meals for people with slow metabolic health and those in recovery from metabolic disorders; this segment is conducted
through Fuzhou Meida.

The following table sets forth the breakdown of our
revenue for the three months ended March 31, 2025 and 2024, respectively:

    Three Months Ended March 31,  
    Variance 

    2025  
    %  
    2024  
    %  
    Amount  
    % 
  
    Rapid diagnostic and other products 
    $40,971  
     100